# Harnessing targeted IL-2 to reduce immunopathology and enhance immunity against respiratory virus infection

> **NIH NIH R01** · UNIVERSITY OF CENTRAL FLORIDA · 2021 · $380,000

## Abstract

Influenza A virus (IAV) remains a global health concern despite annual vaccination efforts. Clinical interventions
able to prevent the immunopathology and `cytokine storm' associated with severe IAV infection are urgently
needed, especially approaches that can be initiated at later stages of infection. The knowledge gained from the
proposed studies will facilitate the development of a novel application of an IL-2-based therapeutic approach to
treat severe respiratory viral infection, as well as advance its potential use as an adjuvant to boost universal,
IAV-specific immunity following vaccination.

## Key facts

- **NIH application ID:** 10334690
- **Project number:** 1R01AI165406-01
- **Recipient organization:** UNIVERSITY OF CENTRAL FLORIDA
- **Principal Investigator:** Tara Marlene Strutt
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $380,000
- **Award type:** 1
- **Project period:** 2021-09-22 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10334690

## Citation

> US National Institutes of Health, RePORTER application 10334690, Harnessing targeted IL-2 to reduce immunopathology and enhance immunity against respiratory virus infection (1R01AI165406-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10334690. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*